Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
0.5 ml |
Concentrate |
RUO |
Z2003MS-R |
-
|
Host |
Mouse |
Klon |
4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
0.1 ml |
Concentrate |
RUO |
Z2003MT-R |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
1 ml |
Concentrate |
CE/IVD |
Z2380ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
7 ml |
Ready-to-use |
CE/IVD |
Z2380MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
0.5 ml |
Concentrate |
CE/IVD |
Z2380MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin or prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human p63 protein |
Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
0.1 ml |
Concentrate |
CE/IVD |
Z2380MT |
-
|
Host |
Mouse + Rabbit |
Klon |
4A4+EP42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1+Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
p63 + Cytokeratin 5 (Lung Squamous-2 TM)
|
Biocare Medical |
4A4+EP42 |
6 ml |
Ready-to-use |
CE/IVD |
PM391DSAA |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
1 ml |
Concentrate |
CE/IVD |
Z2620RL |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
7 ml |
Ready-to-use |
CE/IVD |
Z2620RP |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
0.5 ml |
Concentrate |
CE/IVD |
Z2620RS |
-
|
Host |
Rabbit |
Klon |
ZR316 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Breast lobular carcinoma, melanom |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
0.1 ml |
Concentrate |
CE/IVD |
Z2620RT |
-
|
Host |
Mouse + Rabbit |
Klon |
98/pp120 + EP6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Rabbit IgG |
Lokalisation |
Cytoplasm (p120) and cell membrane (E-Cadherin) |
p120 + E-Cadherin (LC/DC Breast Cocktail)
|
Biocare Medical |
98/pp120 + EP6 |
6 ml |
Ready-to-use |
CE/IVD |
API3011DSAA |
-
|
Host |
Mouse |
Klon |
98/pp120 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
1:100 - 1:250 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3008A |
-
|
Host |
Mouse |
Klon |
98/pp120 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
1:100 - 1:250 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nuclear |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3008B |
-
|
Host |
Mouse |
Klon |
98/pp120 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nuclear |
p120, Catenin (delta)
|
Biocare Medical |
98/pp120 |
6 ml |
Ready-to-use |
CE/IVD |
API3008AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
16 ml |
Ready-to-use |
RUO |
BRB035 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR046 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
6 ml |
Ready-to-use |
RUO |
RBG002 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
RBK002 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit Ig |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK002-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP134 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP134-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP134-05 |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:150 |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
1 ml |
Concentrate |
CE/IVD |
Z2001RL |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2001RP |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:150 |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2001RS |
-
|
Host |
Rabbit |
Klon |
13H4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:150 |
Isotyp |
IgG |
Verdünnung |
Human AMACR (P504S) polypeptide |
Lokalisation |
Cytoplasm |
P504S (AMACR)
|
Zeta Corporation |
13H4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2001RT |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
16 ml |
Ready-to-use |
RUO |
BMS026 |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
1 ml |
Concentrate |
RUO |
CO002K |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
0.5 ml |
Concentrate |
RUO |
CO002K-05 |
-
|
Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
6 ml |
Ready-to-use |
RUO |
COG002 |
-
|
Host |
Mouse |
Klon |
4A4 + XM26 + LL002 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2a, IgG1, IgG3 |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4 + XM26 + LL002 |
16 ml |
Ready-to-use |
RUO |
BMS051 |
-
|
Host |
Mouse |
Klon |
4A4+XM26+LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
1 ml |
Concentrate |
RUO |
CO005K |
-
|
Host |
Mouse |
Klon |
4A4+XM26+LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
0.5 ml |
Concentrate |
RUO |
CO005K-05 |
-
|
Host |
Mouse |
Klon |
4A4+XM26+LL002 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
6 ml |
Ready-to-use |
RUO |
COG005 |
-
|
Host |
Mouse |
Klon |
PD7/26/16+2B11+L26+PS1+DF-T1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil or B-cell lmyphoma or T-cell lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 and Mouse IgG2 |
Lokalisation |
Cell Surface |
pan Lymphoma Cocktail
|
Biocare Medical |
PD7/26/16+2B11+L26+PS1+DF-T1 |
6 ml |
Ready-to-use |
CE/IVD |
API3035AA |
-
|
Host |
Mouse+Rabbit |
Klon |
M2-7C10+M2-9E3+T311+SP6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
MouseIgG2a+IgG2b/kappa+rabbit IgG |
Lokalisation |
Nuclear, cytoplasmic |
Pan Melanoma + Ki-67
|
Biocare Medical |
M2-7C10+M2-9E3+T311+SP6 |
6 ml |
Ready-to-use |
CE/IVD |
PM362DSAA |
-
|
Host |
Mouse+Rabbit |
Klon |
M2-7C10+M2-9E3+T311+SP6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
MouseIgG2a+IgG2b/kappa+IgG2b/kappa+rabbit IgG |
Lokalisation |
Nuclear, cytoplasmic |
Pan Melanoma + Ki-67
|
Biocare Medical |
M2-7C10+M2-9E3+T311+SP6 |
25 ml |
Ready-to-use |
CE/IVD |
PM362DSH |
-
|
Host |
Mouse |
Klon |
M2-7C10+M2-9E3+T311 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 or pH 6.0 |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2b+IgG2b+IgG2a |
Lokalisation |
Cytoplasmic |
Pan Melanoma Cocktail-2
|
Biocare Medical |
M2-7C10+M2-9E3+T311 |
0.1 ml |
Concentrate |
CE/IVD |
CM178A |
-
|
Host |
Mouse |
Klon |
M2-7C10+M2-9E3+T311 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 or pH 6.0 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2b+IgG2b+IgG2a |
Lokalisation |
Cytoplasmic |
Pan Melanoma Cocktail-2
|
Biocare Medical |
M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
PM178AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR176 |
-
|
Host |
Rabbit |
Klon |
EPR17341 |
Format |
Concentrate |
Reaktivität |
CH |
Methode |
P, WB, IF |
Vorbehandlung |
EDTA |
Positivkontrolle |
Astrocytoma, Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
pan Trk
|
Zytomed Systems GmbH |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
RBK069-01 |
-
|
Host |
Rabbit |
Klon |
EPR17341 |
Format |
Concentrate |
Reaktivität |
CH |
Methode |
P, WB, IF |
Vorbehandlung |
EDTA |
Positivkontrolle |
Astrocytoma, Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
pan Trk
|
Zytomed Systems GmbH |
EPR17341 |
0.5 ml |
Concentrate |
RUO |
RBK069-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP176 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP176-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP176-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP030 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP030-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP030-05 |
-
|
Host |
Rabbit |
Klon |
SP151 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Parathyroid glands |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human PTH protein |
Lokalisation |
Cytoplasm |
Parathyroid Hormone (PTH)
|
Zytomed Systems GmbH |
SP151 |
1 ml |
Concentrate |
RUO |
516-4514 |
-
|